SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics
TRIL 20.74+1.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: semi_infinite who wrote (249)2/2/2019 5:37:04 PM
From: scaram(o)uche   of 294
 
Cool paper! Thanks. And what do we get from R&D at Trillium? Isotype swap.

>> Any comments on pros and cons of bspec vs combo approaches? <<

I'd characterize this evidence in favor of bispecific as weak. Pet peeve.... groups of five WT mice. Why not 20? Figures 4b and 4d are perhaps rigged for visual pleasure, extending to only ten days beyond the point where all combo mice have died. Grain of salt, data points in favor of the bispecific.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News